These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain). Ruiz de Sabando A; Urrutia Lafuente E; García-Amigot F; Alonso Sánchez A; Morales Garofalo L; Moreno S; Ardanaz E; Ramos-Arroyo MA BMC Cancer; 2019 Nov; 19(1):1145. PubMed ID: 31771539 [TBL] [Abstract][Full Text] [Related]
3. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Oh M; Alkhushaym N; Fallatah S; Althagafi A; Aljadeed R; Alsowaida Y; Jeter J; Martin JR; Babiker HM; McBride A; Abraham I Prostate; 2019 Jun; 79(8):880-895. PubMed ID: 30900310 [TBL] [Abstract][Full Text] [Related]
4. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. Zhu Y; Wu J; Zhang C; Sun S; Zhang J; Liu W; Huang J; Zhang Z Oncotarget; 2016 Oct; 7(43):70113-70127. PubMed ID: 27659521 [TBL] [Abstract][Full Text] [Related]
5. Genomic Profiling Comparison of Germline Huang X; Shao D; Wu H; Zhu C; Guo D; Zhou Y; Chen C; Lin Y; Lu T; Zhao B; Wang C; Sun Q Front Oncol; 2020; 10():583314. PubMed ID: 33194720 [No Abstract] [Full Text] [Related]
6. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer. Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364 [TBL] [Abstract][Full Text] [Related]
8. Germline breast cancer susceptibility gene mutations and breast cancer outcomes. Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657 [TBL] [Abstract][Full Text] [Related]
9. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Foulkes WD; Chappuis PO; Wong N; Brunet JS; Vesprini D; Rozen F; Yuan ZQ; Pollak MN; Kuperstein G; Narod SA; Bégin LR Ann Oncol; 2000 Mar; 11(3):307-13. PubMed ID: 10811497 [TBL] [Abstract][Full Text] [Related]
10. Reproductive factors as risk modifiers of breast cancer in Park B; Hopper JL; Win AK; Dowty JG; Sung HK; Ahn C; Kim SW; Lee MH; Lee J; Lee JW; Kang E; Yu JH; Kim KS; Moon BI; Han W; Noh DY; Park SK; Oncotarget; 2017 Nov; 8(60):102110-102118. PubMed ID: 29254229 [TBL] [Abstract][Full Text] [Related]
11. Prognostic role of Maksimenko J; Irmejs A; Nakazawa-Miklasevica M; Melbarde-Gorkusa I; Trofimovics G; Gardovskis J; Miklasevics E Oncol Lett; 2014 Jan; 7(1):278-284. PubMed ID: 24348864 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis. Xu K; Yang S; Zhao Y Oncotarget; 2017 Jan; 8(1):285-302. PubMed ID: 27690218 [TBL] [Abstract][Full Text] [Related]
13. Molecular characteristics of breast cancer according to clinicopathological factors. Huszno J; Kolosza Z Mol Clin Oncol; 2019 Aug; 11(2):192-200. PubMed ID: 31281656 [TBL] [Abstract][Full Text] [Related]
14. Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. Huzarski T; Byrski T; Gronwald J; Górski B; Domagala P; Cybulski C; Oszurek O; Szwiec M; Gugala K; Stawicka M; Morawiec Z; Mierzwa T; Janiszewska H; Kilar E; Marczyk E; Kozak-Klonowska B; Siolek M; Surdyka D; Wisniowski R; Posmyk M; Sun P; Lubinski J; Narod SA J Clin Oncol; 2013 Sep; 31(26):3191-6. PubMed ID: 23940229 [TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG. Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974 [TBL] [Abstract][Full Text] [Related]
16. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. Schmidt MK; van den Broek AJ; Tollenaar RA; Smit VT; Westenend PJ; Brinkhuis M; Oosterhuis WJ; Wesseling J; Janssen-Heijnen ML; Jobsen JJ; Jager A; Voogd AC; van Leeuwen FE; van 't Veer LJ J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376189 [TBL] [Abstract][Full Text] [Related]
17. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742 [TBL] [Abstract][Full Text] [Related]
18. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know. Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561 [TBL] [Abstract][Full Text] [Related]
19. The risk factors of toxicity during chemotherapy and radiotherapy in breast cancer patients according to the presence of BRCA gene mutation. Huszno J; Budryk M; Kołosza Z; Nowara E Contemp Oncol (Pozn); 2015; 19(1):72-6. PubMed ID: 26199574 [TBL] [Abstract][Full Text] [Related]
20. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1. Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ; J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]